Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NWB7
UPID:
IFT57_HUMAN
Alternative names:
Dermal papilla-derived protein 8; Estrogen-related receptor beta-like protein 1; HIP1-interacting protein; MHS4R2
Alternative UPACC:
Q9NWB7; Q96DA9
Background:
Intraflagellar transport protein 57 homolog (IFT57) plays a pivotal role in cilia formation and sonic hedgehog signaling, essential for cellular communication and development. It interacts with HIP1 to induce apoptosis and may regulate transcription of caspase genes, highlighting its multifunctionality. Known by alternative names such as Dermal papilla-derived protein 8 and Estrogen-related receptor beta-like protein 1, IFT57's complexity is underscored by its DNA-binding capability.
Therapeutic significance:
IFT57's involvement in Orofaciodigital syndrome 18, characterized by distinct facial and digital malformations, underscores its therapeutic potential. Understanding IFT57's role could open doors to innovative treatments for this and possibly other ciliopathies, leveraging its fundamental biological functions.